1. Anticancer potential of metformin: focusing on gastrointestinal cancers

   • Mohammad rafi Khezri
   • Hassan Malekinejad
   • Morteza Ghasemnejad-Berenji

   Review Article 20 March 2021 Pages: 587 - 598

   

2. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

   • Katharine A. Collier
   • Hugo Valencia
   • Amir Mortazavi

   Original Article 25 January 2021 Pages: 599 - 611

   

3. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours

   • Sunit Sarkar
   • Ben Tran
   • Anne Hamilton

   Original Article 26 January 2021 Pages: 613 - 620

   

4. Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors

   • Reza Khosravan
   • Steven G. DuBois
   • Erjian Wang

   Original Article Open access 28 January 2021 Pages: 621 - 634

   

5. Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach

   • Ling Gao
   • Yiu-Keung Lau
   • Paolo Abada

   Original Article Open access 02 February 2021 Pages: 635 - 645

   

6. Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway

   • Xianglan Yi
   • Liping Lou
   • Sheng Zhou

   Original Article 05 February 2021 Pages: 647 - 656

   

7. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population

   • Jatta Saarenheimo
   • Nesna Wahid
   • André B. P. van Kuilenburg

   Original Article 05 February 2021 Pages: 657 - 663

   

8. Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)

   • Keiichiro Ishibashi
   • Toru Aoyama
   • Hideyuki Mishima

   Original Article Open access 08 February 2021 Pages: 665 - 672

   

9. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

   • Filipa Lynce
   • James T. Williams
   • Beth Overmoyer

   Original Article 14 February 2021 Pages: 673 - 679

10. Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine

    • Duo Liu
    • Xuehua Li
    • Mei Dong

    Original Article 14 February 2021 Pages: 681 - 687

    

11. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

    • Chao Li
    • Lowell Hart
    • Jessica A. Sorrentino

    Original Article Open access 17 February 2021 Pages: 689 - 700

    

12. Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis

    • Yang Liu
    • Yongde Cao
    • Haijiang Wang

    Original Article 21 February 2021 Pages: 701 - 710

    

13. Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk

    • Kathryn E. Burns
    • Ottiniel Chavani
    • Nuala A. Helsby

    Short Communication 09 March 2021 Pages: 711 - 716

    

14. Detecting DPD deficiency: when perfect is the enemy of good

    • Joseph Ciccolini
    • Gérard Milano
    • Henk-Jan Guchelaar

    Letter to the Editor 09 March 2021 Pages: 717 - 719

15. Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level

    • Anjing Gong
    • Na Ge
    • Hui Liang

    Retraction Note 26 October 2020 Pages: 721 - 721